MedTrace Logo

Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma

NCT02767674 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 258

Last updated 2019-01-03

No results posted yet for this study

Summary

The purpose of this study is to investigate efficacy and safety of R-GemOx Versus R-miniCHOP as first-line treatment of elderly patients with Diffuse large B cell lymphoma

Conditions

Interventions

DRUG

Rituximab

375 mg/m2 IVD day0

DRUG

Gemcitabine

Gemcitabine 1 g/m2 IVD day 1

DRUG

Oxaliplatin

Oxaliplatin 100 mg/m2 IVD day1

DRUG

Cyclophosphamide

Cyclophosphamide 400 mg/m2 IVD d1

DRUG

Epirubicin Injectable Product

Epirubicin 35 mg/m2 IVD d1

DRUG

Vindesine

Vindesine 2 mg IVP d1

DRUG

Prednisone

Prednisone 40mg/m2 PO d1-5

Sponsors & Collaborators

  • The First Affiliated Hospital with Nanjing Medical University

    lead OTHER

Principal Investigators

  • Wei Xu, M.D., Ph.D. · The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
70 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02767674 on ClinicalTrials.gov